Usage Information
Citation Information: JCI Insight. 2024;9(18):e181968. https://doi.org/10.1172/jci.insight.181968.
Abstract
Current antiretroviral therapy (ART) regimens efficiently limit HIV replication, thereby improving the life expectancy of people living with HIV; however, they also cause metabolic side effects. The ongoing obesity epidemic has resulted in more people with metabolic comorbidities at the time of HIV infection, yet the effect of preexisting metabolic dysregulation on infection sequelae and response to ART is unclear. Here, to investigate the impact of preexisting obesity and insulin resistance on acute infection and subsequent long-term ART, we infected a cohort of lean and obese adult male macaques with SIV and administered ART. The responses of lean and obese macaques to SIV and ART were similar with respect to plasma and cell-associated viral loads, ART drug levels in plasma and tissues, SIV-specific immune responses, adipose tissue and islet morphology, and colon inflammation, with baseline differences between lean and obese groups largely maintained. Both groups exhibited a striking depletion of CD4+ T cells from adipose tissue that did not recover with ART. However, differential responses to SIV and ART were observed for body weight, omental adipocyte size, and the adiponectin/leptin ratio, a marker of cardiometabolic risk. Thus, obesity and insulin resistance had limited effects on multiple responses to acute SIV infection and ART, while several factors that underlie long-term metabolic comorbidities were influenced by prior obesity and insulin resistance. These studies provide the foundation for future investigations into the efficacy of adjunct therapies such as metformin and glucagon-like peptide-1 receptor agonists in the prevention of metabolic comorbidities in people living with HIV.
Authors
Gabriela M. Webb, Kristin A. Sauter, Diana Takahashi, Melissa Kirigiti, Lindsay Bader, Sarah R. Lindsley, Hannah Blomenkamp, Cicely Zaro, Molly Shallman, Casey McGuire, Heather Hofmeister, Uriel Avila, Cleiton Pessoa, Joseph M. Hwang, Allyson McCullen, Matthew Humkey, Jason Reed, Lina Gao, Lee Winchester, Courtney V. Fletcher, Oleg Varlamov, Todd T. Brown, Jonah B. Sacha, Paul Kievit, Charles T. Roberts
Usage data is cumulative from December 2024 through December 2025.
| Usage | JCI | PMC |
|---|---|---|
| Text version | 1,070 | 296 |
| 162 | 20 | |
| Figure | 255 | 0 |
| Table | 35 | 0 |
| Supplemental data | 113 | 12 |
| Citation downloads | 86 | 0 |
| Totals | 1,721 | 328 |
| Total Views | 2,049 | |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.
